title: Bilateral intrahippocampal NAC61-95 effects on behavior and moderation with L-NAME treatment.
abstract: Residues 61-95 of the non-amyloid component (NAC(61-95)) domain of alpha-synuclein are responsible for the aggregation and neurotoxicity of this protein. This study evaluated the effect of N((omega))-nitro-l-arginine methyl ester (l-NAME), a nitric oxide synthase inhibitor, on the behavior of rats bilaterally injected into the CA3 area of the dorsal hippocampus with aggregated NAC(61-95). Twenty-four male Sprague-Dawley rats were trained to respond under an alternating-lever cyclic-ratio (ALCR) operant schedule. When responding was stable, 12 rats were injected bilaterally into the CA3 area of the hippocampus with aggregated NAC(61-95) (5muicro per side; concentration 10(-4)M), the remaining 12 rats were similarly injected with sterile water (SW), six of the NAC(61-95) injected rats and six of the SW injected rats were treated for 90 days post-injections with 0.05mg/ml l-NAME in drinking water available ad libitum. Treatment with l-NAME alleviated NAC(61-95)-induced behavioral deficits, indicated through the measurement of lever switching errors and incorrect lever perseverations under the ALCR schedule, and reduced the number of activated astrocytes proximal to the injection sites.
authors.affiliation: School of Psychology, Queen's University, University Road, Belfast BT71NN, Northern Ireland, United Kingdom. e.ohare@qub.ac.uk
authors.forename: Eugene
authors.initials: E
authors.lastname: O'Hare
authors.forename: Jennifer J
authors.initials: JJ
authors.lastname: Elliott
authors.forename: Peter
authors.initials: P
authors.lastname: Hobson
authors.forename: Shane M
authors.initials: SM
authors.lastname: O'Mara
authors.forename: David
authors.initials: D
authors.lastname: Spanswick
authors.forename: Eun-Mee
authors.initials: EM
authors.lastname: Kim
mesh_terms: D000704:Analysis of Variance; D000818:Animals; D001253:Astrocytes / Q000187:drug effects; D056654:CA3 Region, Hippocampal / Q000187:drug effects*; D003216:Conditioning, Operant / Q000187:drug effects*; D004791:Enzyme Inhibitors / Q000494:pharmacology; D007150:Immunohistochemistry; D008297:Male; D019331:NG-Nitroarginine Methyl Ester / Q000494:pharmacology*; D010446:Peptide Fragments / Q000494:pharmacology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D051844:alpha-Synuclein / Q000494:pharmacology*
chemical_list: D004791:Enzyme Inhibitors; D010446:Peptide Fragments; D051844:alpha-Synuclein; D019331:NG-Nitroarginine Methyl Ester